Navigation Links
Horphag's Prelox(R) Provides Over-the-Counter Solution in Battle Against Erectile Dysfunction
Date:12/3/2007

Research shows men experienced almost 100% increase of overall satisfaction

HOBOKEN, N.J., Dec. 3 /PRNewswire/ -- For couples worldwide, erectile dysfunction (ED) is one of the leading contributors to a man's inability to perform. As millions of men in America each year look for a solution, many seek alternative treatments to prescription medications and surgery that may have dangerous side effects. A new published study reveals that Prelox(R), a patented and proprietary blend of Pycnogenol(R), (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, combined with L-Arginine aspartate, an amino acid, is the natural answer to enhancing erectile quality.

The study, to be published in an upcoming edition of the International Journal of Impotence Research, shows improvement in men with ED after just one day. The study investigated the mechanism involved in relaxation of arteries as it is required for improved blood flow in erectile function. Prelox(R) was found to cause a markedly increased nitric oxide production, the key mediator involved in expanding arteries for elevated blood flow during erections. By the end of the study, all men taking Prelox(R) experienced almost a 100 percent increase of orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction.

Prelox(R) is a patented unique blend of two circulation-enhancing ingredients including Pycnogenol(R), which contains powerful bioflavonoids that originate from plants and help keep blood vessels dilated for optimal blood flow. L-Arginine, an amino acid found in many foods, is the other ingredient coupled with Pycnogenol(R) that ultimately promotes blood flow.

"Pycnogenol(R) and L-Arginine work together to enhance nitric oxide, a crucial chemical for sexual arousal," said Steven Lamm MD, from New York University School of Medicine "Prelox(R) is the perfect solution for men who want the same outcome as other prescription nitric
'/>"/>

SOURCE Horphag
Copyright©2007 PR Newswire.
All rights reserved

14

GOOD

Page: 1 2 3 4

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. Proven Nutrition Provides Energy and Hope to Cancer Fighters
5. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
6. New knock-out gene model provides molecular clues to breast cancer
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. SIV infection of natural hosts provides new insights into HIV disease complexity
9. Microarray provides 3 genomic guides to breast cancer treatment decisions
10. Access Innovations Provides Support Services for Agis Network
11. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... May 18, 2013 The “World Healthcare ... and studies the major market drivers, restraints, and opportunities ... world. , Browse , 89 ... in-depth TOC on "Healthcare IT Market" , ... customization on reports. , The global healthcare IT market ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 During Better ... loss should consider the legal protections they have, including ... problems arise with their child’s treatment or hearing aid ... Since 1927, the American Speech-Language-Hearing Association has used the ... and to promote treatment, such as cochlear implants, which ...
(Date:5/18/2013)... 2013 Adolescents, especially young males, who ... or “K2” are landing in emergency rooms across America. ... drug epidemic with a new treatment program for ... to research from the National Institute on Drug Abuse, ... among American teenagers. In 2012, 11 percent of high ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The ... Gov. John A. Kitzhaber, M.D., (D) to sign a ... by prohibiting minors under the age of 18 from ... become the third state in the nation to enact ... enacted similar indoor tanning bans for minors. Nationwide, 34 ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The topics that ... are scrum framework, scrum roles, scrum meetings, scrum artifacts, and ... (8 PDUs) for attending them. , These trainings are suitable ... is also ideal for those who will be a part ... those who want to explore Agile and Scrum, but are ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 3
... six major factors that affect how happy a woman ... been uncovered. Researchers writing in the open access journal ... well as final breast appearance, there are five other ... from Memorial Sloan-Kettering Cancer Center, New York, led a ...
... for Procrit, Aranesp, experts say, , , THURSDAY, April 30 ... that drugs such as Procrit and Aranesp, often used ... the risk of death and serious adverse events such ... (ESAs), have also been associated in prior studies with ...
... HOUSTON, April 30 As an expectant mother, her first official ... delivery arrives. Here are four unique ideas to make this ... women prescribed bed rest, this can be a vexing time. ... babies) to stay off her feet, but she is still very ...
... , April 30 ... biopharmaceutical company focused on in-licensing, developing and commercializing proprietary ... today announced that it will release its first quarter ... closes on Thursday, May 7, 2009. Cadence management will ...
... to treat Type 2 diabetes may have unintended effects on the ... some patients and a greater risk of pancreatic cancer in long-term ... In a study published in the online edition of the journal ... Center at UCLA found that sitagliptin, sold in pill form as ...
... Thoratec Corporation (Nasdaq: THOR ), a ... save, support and restore failing hearts, today announced that ... quarter of fiscal 2009 on Thursday, May 7.The company ... results and operating activities open to all interested parties ...
Cached Medicine News:Health News:What influences women's opinions on their breast surgery? 2Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 2Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 3Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 4Health News:Four Unique Gifts for Expectant Moms Includes New Technology That Enhances Pre-Natal Bonding 2Health News:Popular diabetes treatment could trigger pancreatitis, pancreatic cancer 2Health News:Popular diabetes treatment could trigger pancreatitis, pancreatic cancer 3Health News:Thoratec Schedules First Quarter Conference Call, Webcast 2
(Date:5/17/2013)... May 17, 2013  Boehringer Ingelheim will contribute ... at the American Thoracic Society International Conference (ATS ... May 17 – 22. Data will ... the treatment of chronic obstructive pulmonary disease (COPD) ... as investigational compounds for asthma, idiopathic pulmonary fibrosis ...
(Date:5/17/2013)... , May 17, 2013 ... developer of oral drug delivery systems, announced today that ... cleared the Company,s Investigational New Drug application(IND) for ORMD-0801, ... pleased to have the FDA clearance to proceed," stated ... "The upcoming trial is a major milestone for Oramed ...
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... March 16 Healthpoint today announced that it has ... of HP802-247 in venous leg ulcers. HP802-247 is a ... is designed to determine the effectiveness of two cell ... with standard care, compared to placebo plus standard care, ...
... Aims To Enhance Precision and Reduce High Failure ... Hamilton, N.J., March 16 ICON (Nasdaq: ... outsourced development services to the pharmaceutical, biotechnology and ... in centralized psychiatric patient evaluation, today announced that ...
Cached Medicine Technology:Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 2Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 3ICON and MedAvante Sign Alliance Agreement 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,409-7) or contact custom...
... samples of moderate viscosity and density. Proven ergonomic design reduces hand fatigue, ... Volume Range (ul) ... 1.0~1.5 Imprecision(%) ... 10 ...
... is a fully adjustable, air-displacement pipette with ... the latest member of the Pipetman family, ... accuracy, and precision. We also added a ... our customers. Eight models cover the full ...
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Medicine Products: